CN102151289B - 一种人凝血酶原复合物的生产方法 - Google Patents
一种人凝血酶原复合物的生产方法 Download PDFInfo
- Publication number
- CN102151289B CN102151289B CN2011100307938A CN201110030793A CN102151289B CN 102151289 B CN102151289 B CN 102151289B CN 2011100307938 A CN2011100307938 A CN 2011100307938A CN 201110030793 A CN201110030793 A CN 201110030793A CN 102151289 B CN102151289 B CN 102151289B
- Authority
- CN
- China
- Prior art keywords
- gel
- goods
- virus
- inactivation
- protein liquid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 7
- 101000651439 Homo sapiens Prothrombin Proteins 0.000 title abstract 4
- 229940039715 human prothrombin Drugs 0.000 title abstract 4
- 241000700605 Viruses Species 0.000 claims abstract description 34
- 230000002779 inactivation Effects 0.000 claims abstract description 30
- 210000002381 plasma Anatomy 0.000 claims abstract description 21
- 238000000926 separation method Methods 0.000 claims abstract description 11
- 238000000605 extraction Methods 0.000 claims abstract description 9
- 239000003599 detergent Substances 0.000 claims abstract description 6
- 238000007670 refining Methods 0.000 claims abstract description 6
- 239000007788 liquid Substances 0.000 claims description 39
- 102000004169 proteins and genes Human genes 0.000 claims description 33
- 108090000623 proteins and genes Proteins 0.000 claims description 33
- 239000000499 gel Substances 0.000 claims description 32
- 239000000243 solution Substances 0.000 claims description 25
- 238000000108 ultra-filtration Methods 0.000 claims description 25
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 20
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 18
- 239000001509 sodium citrate Substances 0.000 claims description 15
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 claims description 15
- 229940038773 trisodium citrate Drugs 0.000 claims description 15
- 238000005406 washing Methods 0.000 claims description 15
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 10
- DPDMMXDBJGCCQC-UHFFFAOYSA-N [Na].[Cl] Chemical compound [Na].[Cl] DPDMMXDBJGCCQC-UHFFFAOYSA-N 0.000 claims description 10
- 238000004108 freeze drying Methods 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 10
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 10
- 229920000053 polysorbate 80 Polymers 0.000 claims description 10
- 238000004094 preconcentration Methods 0.000 claims description 10
- 230000001681 protective effect Effects 0.000 claims description 10
- 239000011780 sodium chloride Substances 0.000 claims description 10
- 238000003756 stirring Methods 0.000 claims description 10
- STCOOQWBFONSKY-UHFFFAOYSA-N tributyl phosphate Chemical compound CCCCOP(=O)(OCCCC)OCCCC STCOOQWBFONSKY-UHFFFAOYSA-N 0.000 claims description 10
- 108010076282 Factor IX Proteins 0.000 claims description 9
- 229960000027 human factor ix Drugs 0.000 claims description 9
- 239000011543 agarose gel Substances 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 6
- 239000004471 Glycine Substances 0.000 claims description 5
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 5
- 239000000385 dialysis solution Substances 0.000 claims description 5
- 229960002897 heparin Drugs 0.000 claims description 5
- 229920000669 heparin Polymers 0.000 claims description 5
- 238000012856 packing Methods 0.000 claims description 5
- 239000006228 supernatant Substances 0.000 claims description 5
- 230000008961 swelling Effects 0.000 claims description 5
- 238000011282 treatment Methods 0.000 claims description 5
- 238000010792 warming Methods 0.000 claims description 5
- 229920005654 Sephadex Polymers 0.000 claims description 4
- 239000012507 Sephadex™ Substances 0.000 claims description 4
- 238000000034 method Methods 0.000 abstract description 16
- 108010039209 Blood Coagulation Factors Proteins 0.000 abstract description 5
- 102000015081 Blood Coagulation Factors Human genes 0.000 abstract description 5
- 239000003114 blood coagulation factor Substances 0.000 abstract description 5
- 230000000694 effects Effects 0.000 abstract description 4
- 230000004913 activation Effects 0.000 abstract description 2
- 238000001994 activation Methods 0.000 abstract description 2
- 229940019700 blood coagulation factors Drugs 0.000 abstract 1
- 239000003960 organic solvent Substances 0.000 abstract 1
- 238000007725 thermal activation Methods 0.000 abstract 1
- 239000000047 product Substances 0.000 description 10
- 108090000190 Thrombin Proteins 0.000 description 5
- 229960004072 thrombin Drugs 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 4
- 238000002679 ablation Methods 0.000 description 3
- 230000009977 dual effect Effects 0.000 description 3
- 230000000937 inactivator Effects 0.000 description 3
- 229940024790 prothrombin complex concentrate Drugs 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 2
- 239000010836 blood and blood product Substances 0.000 description 2
- 229940125691 blood product Drugs 0.000 description 2
- 230000009849 deactivation Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000007669 thermal treatment Methods 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- 102100022641 Coagulation factor IX Human genes 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 208000009429 hemophilia B Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
Images
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2011100307938A CN102151289B (zh) | 2011-01-28 | 2011-01-28 | 一种人凝血酶原复合物的生产方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2011100307938A CN102151289B (zh) | 2011-01-28 | 2011-01-28 | 一种人凝血酶原复合物的生产方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102151289A CN102151289A (zh) | 2011-08-17 |
CN102151289B true CN102151289B (zh) | 2013-04-17 |
Family
ID=44433178
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2011100307938A Active CN102151289B (zh) | 2011-01-28 | 2011-01-28 | 一种人凝血酶原复合物的生产方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102151289B (zh) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102441172B (zh) * | 2011-12-06 | 2014-05-07 | 中国医学科学院输血研究所 | 高纯度凝血酶原复合物制品冷冻干燥稳定剂 |
CN102488710A (zh) * | 2011-12-14 | 2012-06-13 | 吉林大学 | 一种从猪血浆中提取凝血酶拮抗剂的方法 |
WO2016161422A1 (en) * | 2015-04-02 | 2016-10-06 | Kieu Hoang | A method of manufacturing and purifiying prothrombin complex concentrate from fraction iii for intraveneous injection and a method of curing and preventing hemophilia a with inhibitors or hempophilia b patients infected with hiv-1 and hiv-2 |
CN106474461B (zh) * | 2015-08-24 | 2019-12-27 | 上海洲跃生物科技有限公司 | 制备冻干人凝血酶的方法 |
CN105250226B (zh) * | 2015-09-30 | 2018-05-08 | 武汉海特生物制药股份有限公司 | 一种猪凝血酶冻干粉的制备方法 |
CN105326859A (zh) * | 2015-11-09 | 2016-02-17 | 上海洲跃生物科技有限公司 | 一种从Cohn血浆组分III中制备人凝血酶原复合物的方法 |
CN105879038B (zh) * | 2016-05-27 | 2020-03-27 | 成都蓉生药业有限责任公司 | 一种制备人凝血酶原复合物的干热处理稳定剂及其用途 |
CN105821024A (zh) * | 2016-05-30 | 2016-08-03 | 成都蓉生药业有限责任公司 | 一种制备人凝血酶原复合物的方法 |
CN108441490B (zh) * | 2018-04-02 | 2021-11-30 | 博雅生物制药集团股份有限公司 | 一种流动吸附法制备人凝血酶原复合物的工艺 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1475569A (zh) * | 2002-08-15 | 2004-02-18 | 华兰生物工程股份有限公司 | 冻干人凝血酶原复合物的生产方法 |
CN101439047A (zh) * | 2007-11-20 | 2009-05-27 | 山东泰邦生物制品有限公司 | 提高人凝血酶原复合物稳定性fvii得率的工艺方法 |
-
2011
- 2011-01-28 CN CN2011100307938A patent/CN102151289B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1475569A (zh) * | 2002-08-15 | 2004-02-18 | 华兰生物工程股份有限公司 | 冻干人凝血酶原复合物的生产方法 |
CN101439047A (zh) * | 2007-11-20 | 2009-05-27 | 山东泰邦生物制品有限公司 | 提高人凝血酶原复合物稳定性fvii得率的工艺方法 |
Non-Patent Citations (11)
Title |
---|
人凝血酶原复合物分离纯化工艺的研究进展;邱家山等;《生物技术通报》;20060426(第02期);17-20、24 * |
冻干人凝血酶原复合物的生产工艺研究;魏舒等;《中国输血杂志》;20080425(第04期);282-284,1.2节方法②及图1 * |
凝血酶原复合物的制备及其临床应用进展;焦丽华等;《中国输血杂志》;20080925(第09期);737-741 * |
刘欣晏等.采用两步凝胶吸附法制备人凝血酶原复合物的工艺研究.《中国生化药物杂志》.2008,(第01期),26-29. |
刘隽湘.凝血酶原复合物和纯化因子Ⅸ浓制剂.《输血疗法与血液制剂》.1996,220-225. * |
孙锦光等.病毒灭活人凝血酶原复合物的研究.《山东医药工业》.2001,(第01期),5-6. |
焦丽华等.凝血酶原复合物的制备及其临床应用进展.《中国输血杂志》.2008,(第09期),737-741. |
病毒灭活人凝血酶原复合物的研究;孙锦光等;《山东医药工业》;20010215(第01期);5-6 * |
邱家山等.人凝血酶原复合物分离纯化工艺的研究进展.《生物技术通报》.2006,(第02期),17-20、24. |
采用两步凝胶吸附法制备人凝血酶原复合物的工艺研究;刘欣晏等;《中国生化药物杂志》;20080220(第01期);26-29 * |
魏舒等.冻干人凝血酶原复合物的生产工艺研究.《中国输血杂志》.2008,(第04期),282-284. |
Also Published As
Publication number | Publication date |
---|---|
CN102151289A (zh) | 2011-08-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102151289B (zh) | 一种人凝血酶原复合物的生产方法 | |
CN102580062B (zh) | 人凝血因子VIII与vWF复合物或人凝血因子VIII制剂的干热处理稳定剂 | |
CN105385737A (zh) | 一种牦牛骨胶原寡肽的制备工艺 | |
JP6820232B2 (ja) | アニオン交換クロマトグラフィーによるタンパク質の精製 | |
CN106497949A (zh) | 一种高活性凝血因子ix突变体、重组蛋白与融合蛋白的制备与应用 | |
CN104672328A (zh) | 一种人抗凝血酶ⅲ的生产方法 | |
CN103405754B (zh) | 用于生产人纤维蛋白原的增溶工艺 | |
CN102614219A (zh) | 一种高收率人凝血酶原复合物的制备方法 | |
CN102604920A (zh) | 人凝血酶原复合物的制备方法 | |
CN105175486A (zh) | 一种高纯人凝血因子ix的制备方法 | |
CN105294858A (zh) | 一种冻干人凝血因子viii的制备方法 | |
CN105326859A (zh) | 一种从Cohn血浆组分III中制备人凝血酶原复合物的方法 | |
US5393666A (en) | Method of activating prothrombin | |
CA2212832C (en) | Thrombin preparation | |
CN101439047B (zh) | 提高人凝血酶原复合物稳定性fvii得率的工艺方法 | |
CN113652414B (zh) | 一种高纯人凝血酶的制备方法 | |
CN102430116A (zh) | 用于人凝血因子ⅷ制剂的干热处理方法及其稳定剂 | |
CN105440127B (zh) | 一种以人血浆Cohn组分III为原料的FEIBA的制备方法 | |
JP2839712B2 (ja) | 第▲ix▼因子の精製 | |
CN102416171A (zh) | 高纯度凝血酶原复合物制品干热病毒灭活过程中的保护剂 | |
CN103041380B (zh) | 人抗凝血酶制剂干热处理过程中的稳定剂 | |
CN106011116A (zh) | 一种人凝血酶的制备方法 | |
CN106474461B (zh) | 制备冻干人凝血酶的方法 | |
CN115814099B (zh) | 一种人凝血因子ix的干热处理稳定剂及其制剂与制备方法 | |
JP6612472B2 (ja) | 血液凝固第vii因子の高収率回収のためのクロマトグラフィー法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C53 | Correction of patent for invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Yang Jinping Inventor after: Yang Li Inventor after: Li Changlu Inventor after: Sun Xiaodong Inventor after: Chen Fengzhu Inventor after: Yu Yang Inventor after: Guo Jing Inventor before: Yang Jinping Inventor before: Wei Shu Inventor before: Li Changlu Inventor before: Sun Xiaodong Inventor before: Chen Fengzhu Inventor before: Yu Yang Inventor before: Guo Jing |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: YANG JINPING WEI SHU LI CHANGLU SUN XIAODONG CHEN FENGZHU YU YANG GUO JING TO: YANG JINPING YANG LI LI CHANGLU SUN XIAODONG CHEN FENGZHU YU YANG GUO JING |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Method for producing human prothrombin complex Effective date of registration: 20130516 Granted publication date: 20130417 Pledgee: Bank of Hankou Limited by Share Ltd Sales Department Pledgor: Harbin Paisi Feike Biological Pharmaceutical Co., Ltd. Registration number: 2013990000285 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20150312 Granted publication date: 20130417 Pledgee: Bank of Hankou Limited by Share Ltd Sales Department Pledgor: Harbin Paisi Feike Biological Pharmaceutical Co., Ltd. Registration number: 2013990000285 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Method for producing human prothrombin complex Effective date of registration: 20150313 Granted publication date: 20130417 Pledgee: Bank of Hankou Limited by Share Ltd Sales Department Pledgor: Harbin Paisi Feike Biological Pharmaceutical Co., Ltd. Registration number: 2015990000191 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20160413 Granted publication date: 20130417 Pledgee: Bank of Hankou Limited by Share Ltd Sales Department Pledgor: Harbin Paisi Feike Biological Pharmaceutical Co., Ltd. Registration number: 2015990000191 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Method for producing human prothrombin complex Effective date of registration: 20160418 Granted publication date: 20130417 Pledgee: Bank of Hankou Limited by Share Ltd Sales Department Pledgor: Harbin Paisi Feike Biological Pharmaceutical Co., Ltd. Registration number: 2016990000303 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20180420 Granted publication date: 20130417 Pledgee: Bank of Hankou Limited by Share Ltd Sales Department Pledgor: Harbin Paisi Feike Biological Pharmaceutical Co., Ltd. Registration number: 2016990000303 |
|
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: No.77 Siping Road, Limin Economic Development Zone, Hulan District, Harbin City, Heilongjiang Province Patentee after: Harbin pesfico biopharmaceutical Co.,Ltd. Address before: 150078 No. 640 Airport Road, Daoli District, Heilongjiang, Harbin Patentee before: HARBIN PAISI FEIKE BIOLOGICAL PHARMACEUTICAL Co.,Ltd. |